ATS Corporation (ATS)
| Market Cap | 3.03B +10.3% |
| Revenue (ttm) | 2.13B +17.4% |
| Net Income | 51.32M |
| EPS | 0.52 |
| Shares Out | 97.00M |
| PE Ratio | 56.77 |
| Forward PE | 21.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,179 |
| Open | 30.35 |
| Previous Close | 30.92 |
| Day's Range | 29.19 - 30.63 |
| 52-Week Range | 23.85 - 35.82 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 35.00 (+17.96%) |
| Earnings Date | May 28, 2026 |
About ATS
ATS Corporation, together with its subsidiaries, provides automation solutions worldwide. The company is involved in planning, designing, building, commissioning, and servicing automated manufacturing and assembly systems, including automation products and test solutions. It also offers pre-automation services comprising discovery and analysis, concept development, simulation, and total cost of ownership modelling; post-automation services, including training, process optimization, preventative maintenance, emergency and on-call support, spare ... [Read more]
Analyst Summary
According to 7 analysts, the average rating for ATS stock is "Buy." The 12-month stock price target is $35.0, which is an increase of 17.96% from the latest price.
News
ATS Corporation Slides: Investor presentation
ATS Corporation has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
ATS Q4 Earnings Call Highlights
ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outlining a series of restructuring actions aimed at improving margins, cash generation and capital effic...
ATS Corporation Earnings Call Transcript: Q4 2026
Revenue and adjusted earnings grew 11% year-over-year, with Q4 margins and cash flow improving. Fiscal 2027 guidance calls for modest revenue growth and 50-75 bps margin expansion, supported by a CAD 2B backlog and strong life sciences and energy segments.
ATS Corporation Slides: Q4 2026
ATS Corporation has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 28, 2026.
ATS Corporation Registration statement: Q4 2026
ATS Corporation filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
ATS Corporation Registration statement: Q4 2026
ATS Corporation filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
ATS Corporation Annual report: Q4 2026
ATS Corporation has published its Q4 2026 annual report on May 28, 2026.
ATS Corporation Earnings release: Q4 2026
ATS Corporation released its Q4 2026 earnings on May 28, 2026, summarizing the period's financial results.
ATS Corporation Earnings release: Q4 2026
ATS Corporation released its Q4 2026 earnings on May 28, 2026, summarizing the period's financial results.
ATS Corporation sees Q1 revenue $700M-$740M, consensus $758.64M
06:06 EDT ATS Corporation (ATS) sees Q1 revenue $700M-$740M, consensus $758.64M
ATS Corporation sees FY27 revenue growth “modest”, consensus $2.96B
Management believes that the underlying trends driving customer demand for ATS solutions, including growing labour constraints, production onshoring or reshoring and the need for scalable, high-qualit...
ATS Corporation reports Q4 adjusted EPS 36c, consensus 32c
Reports Q4 revenue $747.1M, consensus $732.14M. “Today ATS reported fourth quarter and full-year results for fiscal 2026, with full-year revenue and adjusted earnings from operations growth of approxi...
ATS Reports Fourth Quarter Fiscal 2026 Results
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2026. All referen...
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 Internati...
ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the fourth quarter ended March 31, 2026, before markets open ...
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse...
ATS Corporation price target raised to C$51 from C$48 at Scotiabank
Scotiabank raised the firm’s price target on ATS Corporation (ATS) to C$51 from C$48 and keeps an Outperform rating on the shares.
ATS Corporation Registration statement: Registration filing
ATS Corporation filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
ATS Corporation price target lowered to $30 from $31 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on ATS Corporation (ATS) to $30 from $31 and keeps a Sell rating on the shares. The firm is updating its models as
ATS to Participate in the TD Cowen Distinctive Industrials and Infrastructure Services Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Doug Wright, Chief Executive Officer, and Anne Cybulski, Interim Chief Financi...
ATS Corporation Transcript: 47th Annual Raymond James Institutional Investor Conference
The incoming CEO outlined a strategy focused on margin expansion, disciplined M&A, and leveraging strengths in life sciences and nuclear markets. Operational improvements, portfolio diversification, and targeted investments in high-margin and service-oriented businesses are key priorities.
ATS to Participate in the Raymond James Institutional Investors Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Doug Wright, Chief Executive Officer, and Anne Cybulski, Interim Chief Financi...
ATS Corporation Slides: Investor presentation
ATS Corporation has posted slides in relation to its latest quarterly earnings report, which was published on February 6, 2026.
ATS Corporation Earnings Call Transcript: Q3 2026
Q3 revenue rose 16.7% year-over-year to $761M, with strong growth in life sciences and energy. Order backlog remains robust at $2.1B, and margin expansion is a key focus. Capital allocation will prioritize M&A and innovation as leverage returns to target range.